Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Public ClinicalTrials.gov record NCT04976634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
Study identification
- NCT ID
- NCT04976634
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 730 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 17, 2021
- Primary completion
- Mar 21, 2027
- Completion
- Mar 21, 2027
- Last update posted
- Apr 5, 2025
2021 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047) | Tucson | Arizona | 85724 | — |
| City of Hope Comprehensive Cancer Center ( Site 5002) | Duarte | California | 91010 | — |
| Cedars-Sinai Medical Center ( Site 5045) | Los Angeles | California | 90048 | — |
| UCSF Medical Center at Mission Bay ( Site 5021) | San Francisco | California | 94158 | — |
| Yale-New Haven Hospital-Yale Cancer Center ( Site 5013) | New Haven | Connecticut | 06510 | — |
| Sibley Memorial Hospital ( Site 5051) | Washington D.C. | District of Columbia | 20016 | — |
| University of Florida College of Medicine ( Site 5015) | Gainesville | Florida | 32610 | — |
| Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 5048) | Baltimore | Maryland | 21287 | — |
| Brigitte Harris Cancer Pavilion ( Site 5055) | Detroit | Michigan | 48202 | — |
| Memorial Sloan Kettering Cancer Center ( Site 5050) | New York | New York | 10065 | — |
| Duke Cancer Institute ( Site 5026) | Durham | North Carolina | 27710 | — |
| University of Texas MD Anderson Cancer Center-Gastrointestinal Medical Oncology ( Site 5049) | Houston | Texas | 77030 | — |
| Inova Schar Cancer Institute ( Site 5039) | Fairfax | Virginia | 22031 | — |
| Blue Ridge Cancer Care ( Site 5053) | Roanoke | Virginia | 24014 | — |
| Northwest Medical Specialties, PLLC ( Site 5025) | Tacoma | Washington | 98405 | — |
| University of Wisconsin Hospitals and Clinics ( Site 5037) | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04976634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04976634 live on ClinicalTrials.gov.